Vitamin D3 for Life

Live Enlightened

Physiology

Childhood Vitamin D, Immune Development and Neurodevelopment: Full Evidence Review

Previous related pageChildhood Vitamin D, Immune Development and Neurodevelopment: Study SummaryNext related pageChildhood Vitamin D, Immune Development and Neurodevelopment: Study Summary
Study at a glance

What was studied?

What do childhood vitamin D studies show about immune and nervous-system development?

What did the studies find?

Four childhood study populations measured immune markers, thinking tasks or school results. Some immune markers changed, but the studies did not establish better immune maturation or a general cognitive benefit. They did not directly measure vitamin D signalling inside nerve cells.

What does this mean?

A laboratory change does not necessarily mean better protection against illness. A thinking test cannot by itself explain a cellular mechanism. These studies leave important developmental questions unanswered.

What are the limits?

Some trials were short or small, and observational studies could not remove every family or social difference. Evidence was limited for severe deficiency. Additional reports were unavailable in full. The findings do not prove that vitamin D has no physiological role or establish a personal blood target.

Read the full article below ↓

Research on childhood vitamin D and development includes blood tests, immune-cell measurements, cognitive tasks and school results. These outcomes answer different questions. This review assesses four independent childhood study populations and an optional comparison involving supplementation during infancy. It distinguishes changes in laboratory markers from evidence of immune maturation, and developmental test results from direct measurements of vitamin D signalling in the nervous system. For the shorter account, read Childhood Vitamin D, Immune Development and Neurodevelopment: Study Summary.

For current UK guidance, including advice for children, see the NHS page Vitamin D.

What would evidence of development actually show?

The blood measurement used in these studies is 25-hydroxyvitamin D, abbreviated to 25(OH)D. It indicates circulating vitamin D status. It is not the same substance as vitamin D3 in a supplement or the active vitamin D hormone. A blood concentration alone does not reveal how a particular immune cell or neuron responds to that hormone. Vitamin D Receptors introduces the cellular response system, which is a different level of measurement.

Immune development is also more than one laboratory result. Researchers may count types of white blood cells, measure molecules released by stimulated cells, or record illnesses. A change in cell proportions does not necessarily mean that a child resists infection better. Conversely, a trial without a detectable change in reported illness cannot rule out every cellular effect. The broader physiological setting is described in Vitamin D and Immunity.

The same distinction applies to the nervous system. Cognitive tests assess performance on defined tasks; school results also reflect teaching, attendance and social circumstances. Neither directly measures signalling inside developing neurons. The childhood studies assessed here do not demonstrate a particular neuronal vitamin D mechanism. They can help answer whether status or an assigned supplement relates to measured function, while leaving the cellular explanation unresolved. How to Read Vitamin D Evidence Across Brain Models explains why these evidence levels cannot substitute for one another.

This is not a claim that vitamin D has no physiological role. It is a statement about what these experiments and observations measured. Vitamin D, Cell Fate and Tissue Structure: Full Evidence Review separately assesses cell maturation and tissue structure, keeping those endpoints distinct from function in a living child. Evidence for a biological pathway and evidence that raising a child’s vitamin D status improves an outcome are different kinds of evidence. One cannot be substituted for the other. The separate review Vitamin D Signalling in Brain Development and Regional Function: Full Study examines tissue and laboratory models; it does not establish developmental benefits in the children studied here.

Montreal: measurable immune differences without proven better immunity

Brett and colleagues reported two linked investigations. One was a cross-sectional study of 457 children aged two to five. A cross-sectional study compares measurements taken around the same period; it cannot establish which factor came first. The other was an ancillary analysis of a randomized food-fortification trial involving 77 children aged two to eight over 12 winter weeks (Brett et al., 2018).

The trial compared fortified foods intended to provide vitamin D intakes of 400 or 600 IU daily with a control condition. IU means international units. These were research intake targets, not personal instructions for children. Food-based interventions also need to be interpreted in their dietary context rather than assumed identical to every tablet or spray regimen.

Endpoint 25(OH)D was approximately 64 nmol/L in the fortified groups compared with 56 nmol/L in controls. Nanomoles per litre describe a concentration in blood. A higher percentage of lymphocytes, a group of white blood cells, was observed in the 600-IU group. However, the proportions of the more specific cell subtypes examined did not show corresponding differences.

The investigators also stimulated cells in the laboratory with concanavalin A, often shortened to ConA. This is a substance used to provoke a cellular response; it is not a bacterial infection. The stimulated release of interleukin-6, an immune signalling molecule, was lower in the fortified groups. Other measured cytokines, the signalling molecules released by cells, and cathelicidin did not show a corresponding consistent advantage. Reported illness outcomes were not different.

These results resist a simple “stronger immunity” interpretation. A lower stimulated concentration of one molecule does not by itself show that an immune system is more mature, better regulated in everyday life, or more effective against infection. The study did not establish those outcomes. The higher lymphocyte percentage also remained a laboratory observation, not a demonstrated clinical benefit. Vitamin D and Innate Responses: Recognition, Peptides and Function: Full Evidence Review similarly distinguishes immune recognition, measured proteins and functional defence.

The cross-sectional component adds a useful qualification. Higher vitamin D status was associated with higher concentrations of some inflammatory markers. That does not establish that vitamin D caused inflammation or harm. Children differed in many characteristics, and the design cannot separate every possible influence. It also prevents the findings from being reduced to a uniform story in which higher status always means lower inflammatory signalling. The translation from a local assay to a whole-body outcome is examined in From Cellular Cytokine Responses to Systemic Inflammation.

The trial’s immune analyses used small subsets. The report gives an inconsistent subset total between its text and table, so a precise combined number should not be inferred. Baseline stimulated measurements showed wide variation despite no statistically detected group differences. The trial was designed primarily around vitamin D status, lasted only 12 weeks and relied on parent-reported illness. These limitations matter more than counting the number of laboratory comparisons that happened to change.

Northern Ireland: a randomized trial with exploratory outcomes

Royle and colleagues assigned 118 children aged four to 11 to vitamin D3 spray or placebo for 12 weeks. The supplement provided 10 micrograms daily. This was a monitored experiment, not an individual dosing recommendation. The main report describes 102 completers and 16 missing endpoint records handled by carrying forward baseline values, although the abstract suggests that all 118 completed (Royle et al., 2026).

The intervention increased circulating status. The adjusted difference in 25(OH)D was 11.72 nmol/L, with a 95% confidence interval from 5.96 to 17.75 nmol/L. A confidence interval expresses uncertainty around an estimated group difference. This result supports a status response under the study conditions; it does not by itself establish improved development.

Cognitive and immune outcomes were exploratory. After adjustment for multiple comparisons, the study did not establish a cognitive or immune advantage. A nonsignificant pattern in a response-time task should not be described as demonstrated neurodevelopmental benefit. The measurements also do not establish that children should aim for a vitamin D concentration above 75 nmol/L to improve immunity.

There were important design limitations. Families were assigned together and many participants were siblings, but the reported analysis treated children as individual observations without a described adjustment for family clustering. Shared household characteristics can make siblings’ results less independent. Missing endpoint data were more frequent in the vitamin D group, and the immune analyses involved smaller, uneven subsets.

Twelve weeks is also a limited period for evaluating development. The trial was primarily powered around a blood-status outcome rather than every cognitive or immune measure. Its result is therefore best expressed as an absence of a demonstrated additional benefit in the outcomes assessed, with limited precision. It is not proof that vitamin D can never affect immune or nervous-system function.

Taken with Montreal, this trial shows why laboratory and functional outcomes need to remain separate. Montreal found selected immune differences without an illness advantage. Royle did not establish a broad immune or cognitive benefit after accounting for multiple testing. Neither experiment directly established accelerated immune maturation or a neuronal signalling mechanism.

ALSPAC: childhood status and later school performance

The British ALSPAC cohort provides a different type of evidence. Tolppanen and colleagues analysed 3,171 children with the required measurements. Vitamin D metabolites were measured at a mean age of 9.8 years, and academic results were assessed at approximately 13 to 14 and 15 to 16 years. This prospective sequence places the blood measurement before the later school outcomes (Tolppanen et al., 2012).

The analysis distinguished 25-hydroxyvitamin D3 from 25-hydroxyvitamin D2. After accounting for season and other measured factors, D3 status was not associated with academic performance. Some weak inverse associations appeared for D2, but these cannot establish that vitamin D2 damages learning. Residual differences in family circumstances or chance remain possible explanations.

Observational adjustment is useful, but it does not turn a cohort into a randomized trial. Families differ in education, resources, health and other characteristics that can affect both nutrition-related measurements and school performance. Some differences can be measured and included in an analysis; others may remain unmeasured or imperfectly recorded.

Selection also limits interpretation. The analysed sample was relatively advantaged, and children with special educational needs were excluded. A single blood sample cannot fully describe exposure throughout childhood. The main paper supports a bounded conclusion about its measured associations; additional sensitivity tables were unavailable for this assessment, so robustness across every supplementary analysis is not claimed.

School performance is valuable in its own right, but it is a broad outcome. An exam result cannot identify whether vitamin D changed a receptor pathway in a neuron. The ALSPAC findings therefore contribute to the functional-development question without providing direct evidence about cellular signalling or an individual child’s learning needs.

Uganda: preschool status and cognitive or motor tasks

Mutua and colleagues studied 302 Ugandan children from the Entebbe Mother and Baby Study. Vitamin D status was measured between one and four years of age, at an average age of about 2.3 years. Cognitive and motor outcomes were assessed at age five. Although the children came from a parent trial of medicines against parasitic worms, vitamin D exposure itself was not randomized in this analysis (Mutua et al., 2020).

Average 25(OH)D was 83.2 nmol/L, and only eight children had concentrations below 50 nmol/L. The study therefore offered little information about children with markedly low status. It mainly examined variation within a population whose measured concentrations were generally higher.

In the adjusted analysis of 259 children, status was not associated with the composite cognitive, executive-function or motor scores. For the cognitive composite, the estimated coefficient was 0.01 per 10 nmol/L, with a confidence interval from −0.07 to 0.08. These were composite-score units, not a change of 0.01 standard IQ points. Executive-function and motor estimates were also close to zero with intervals spanning both directions.

The study used locally adapted assessments and measured status before the later tests. However, the analysed children represented only about 13% of the original cohort. Follow-up selected families with particular social and nutritional characteristics. Home stimulation and maternal cognitive ability were not fully accounted for, and the exposure measurement was taken only once.

This finding does not establish that vitamin D has no developmental importance. It says that differences in the measured status range did not predict the tested outcomes in this selected sample after the reported adjustments. It is a weak basis for judging whether correcting severe deficiency would change development, because very few participating children had low measured status.

The contrast with ALSPAC is useful without being a direct replication. The Ugandan study involved younger children, different tests and a different setting. ALSPAC examined later school outcomes. Their shared absence of a clear positive association does not remove the distinct selection, measurement and confounding limitations of each cohort.

An infancy intervention is a separate timing question

A Finnish follow-up of the Vitamin D Intervention in Infants trial, known as VIDI, assessed children at six to eight years after they had received 400 or 1,200 IU daily during infancy up to 24 months. Seppälä and colleagues reported 398 children with at least one relevant follow-up outcome; fewer completed each individual assessment, including 278 with IQ measurements (Seppälä et al., 2026).

The randomized IQ difference was 1.14 points, with a 95% confidence interval from −1.69 to 3.97. The study did not demonstrate a neurocognitive advantage from the higher infant dose. Attrition selected relatively advantaged families, parents had learned treatment allocation after infancy, and endpoint sample sizes differed. The personnel conducting assessments remained blinded.

This is useful timing context, but it does not test starting supplementation during school years. It is also the same underlying trial as other VIDI infancy and later follow-up reports, not a collection of independent confirmations. An observational association involving maternal status in this paper cannot establish an optimal maternal concentration or a randomized prenatal benefit.

How complete is this assessment?

The four core childhood populations provide directly inspected evidence about the specified outcomes, but this is not an exhaustive systematic review. A Danish trial of innate immune markers, ODIN Junior, was available only at abstract level. It is not counted as a fully assessed study. A fortified-milk cognition study with a visible positive result was also not available in full; its multiple nutrients and DHA mean that its intervention cannot be treated as an isolated vitamin D test.

These access limits prevent a claim that every childhood cognition or immune study agrees. They do not justify inventing unseen results or labelling an unread study poor quality. The conclusion concerns the evidence actually assessed and the questions those studies can answer.

Across the core evidence, changes in selected immune markers did not establish improved immune maturation, and the cognitive or educational findings did not demonstrate a general developmental advantage from higher status. The evidence is limited for severe deficiency, long-term clinical immune development and direct neuronal signalling. Those gaps should remain visible rather than be converted into proof that vitamin D has no role.

The practical scientific distinction is between a plausible biological question and a demonstrated functional benefit. These studies help define what has been measured and what remains uncertain. They do not supply a universal blood target, a personal supplement regimen or a direct explanation of vitamin D signalling inside a developing child’s nervous system.

Scientific sources

Not reportedVitamin D Status and Immune Health Outcomes in a Cross-Sectional Study and a Randomized Trial of Healthy Young Children. Brett NR et al. Nutrients. 2018;10:680. DOI:10.3390/nu10060680.

Not reportedThe Effect of Vitamin D3 Supplementation on Vitamin D Status and Associated Health Outcomes in Children: A Randomized Controlled Trial. Royle E et al. Journal of Nutrition. 2026;156:101493. DOI:10.1016/j.tjnut.2026.101493.

Not reportedAssociation of serum 25-hydroxyvitamin D3 and D2 with academic performance in childhood: findings from a prospective birth cohort. Tolppanen AM et al. Journal of Epidemiology and Community Health. 2012;66:1137 to 1142. DOI:10.1136/jech-2011-200114.

Not reportedVitamin D Status Is Not Associated with Cognitive or Motor Function in Pre-School Ugandan Children. Mutua AM et al. Nutrients. 2020;12:1662. DOI:10.3390/nu12061662.

Not reportedEarly life vitamin D and neurocognitive abilities at age 6 to 8 years: a randomized clinical trial and observational analysis. Seppälä V et al. European Child & Adolescent Psychiatry. 2026;35:587 to 597. DOI:10.1007/s00787-025-02891-7.

Not reportedWinter cholecalciferol supplementation at 55°N has little effect on markers of innate immune defense in healthy children aged 4 to 8 years: a secondary analysis from a randomized controlled trial. Hauger H et al. European Journal of Nutrition. 2019;58:1453 to 1462. Abstract-level access; not counted as fully assessed.

Not reportedEffects of fortified milk on cognitive abilities in school-aged children: results from a randomized-controlled trial. Petrova D et al. European Journal of Nutrition. 2019;58:1863 to 1872. Identifiable institutional publication record; complete paper not assessed. Multinutrient intervention, not an isolated vitamin D test.

Related reading

Original sources

Source

Vitamin D

For current UK guidance, including advice for children, see the NHS page Vitamin D.

Publication details

For current UK guidance, including advice for children, see the NHS page Vitamin D.

Read more →
Source

Association of serum 25-hydroxyvitamin D3 and D2 with academic performance in childhood: findings from a prospective birth cohort

Published in Tolppanen AM et al. Journal of Epidemiology and Community Health (2012).

Publication details

Not reportedAssociation of serum 25-hydroxyvitamin D3 and D2 with academic performance in childhood: findings from a prospective birth cohort. Tolppanen AM et al. Journal of Epidemiology and Community Health. 2012;66:1137 to 1142. DOI:10.1136/jech-2011-200114.

Read more →
Source

Early life vitamin D and neurocognitive abilities at age 6 to 8 years: a randomized clinical trial and observational analysis

Participants were from a Finnish vitamin D double-blind randomized clinical trial and classified themselves white.

Publication details

Not reportedEarly life vitamin D and neurocognitive abilities at age 6 to 8 years: a randomized clinical trial and observational analysis. Seppälä V et al. European Child & Adolescent Psychiatry. 2026;35:587 to 597. DOI:10.1007/s00787-025-02891-7.

Read more →
Source

Winter cholecalciferol supplementation at 55°N has little effect on markers of innate immune defense in healthy children aged 4–8 years: a secondary analysis from a randomized controlled trial

Published in Hauger H et al. European Journal of Nutrition (2019).

Publication details

Not reportedWinter cholecalciferol supplementation at 55°N has little effect on markers of innate immune defense in healthy children aged 4 to 8 years: a secondary analysis from a randomized controlled trial. Hauger H et al. European Journal of Nutrition. 2019;58:1453 to 1462. Abstract-level access; not counted as fully assessed.

Read more →
Source

Effects of fortified milk on cognitive abilities in school-aged children: results from a randomized-controlled trial

Published in Petrova D et al. European Journal of Nutrition (2019).

Publication details

Not reportedEffects of fortified milk on cognitive abilities in school-aged children: results from a randomized-controlled trial. Petrova D et al. European Journal of Nutrition. 2019;58:1863 to 1872. Identifiable institutional publication record; complete paper not assessed. Multinutrient intervention, not an isolated vitamin D test.

Read more →